Folate Receptor (FR)
Folate Receptor (FR)
Folate receptor (FR) is a class of cysteine-rich glycosylphosphatidylinositol-coupled protein that can mediate folate transport from outside to inside cells, and is divided into FR-α, FR-β, and FR-γ Subtypes. FR-α is expressed in renal proximal tubules and in various solid epithelial neoplasms (ovary, endometrium, brain, lung, and renal cancers). FR-β is expressed in normal hematopoietic tissue, activated macrophages, and hematogenous malignancies. Folate receptor can be used for the early diagnosis and study of tumors[1]sup>[2].
Folate Receptor (FR) Isoform Specific Products
All Product Categories
-
Folate Receptor (FR) Related Products (29)
-
Folate Receptor (FR) Isoform Comparison
- 1
- 2
-
EC-17 disodium salt
0 ImagesCat. No.: HY-13615ACAS No.: 910661-33-5EC-17 disodium salt is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The EC-17 maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively. -
loading...loading...
-
-
DSPE-PEG2000-Folate
0 ImagesCat. No.: HY-W440888Synonyms: DSPE-PEG2000(2000) FolateDSPE-PEG2000-Folate (DSPE-PEG2000 Folate) is a folate-containing PEG derivative. DSPE-PEG2000-Folate possesses targeting activity and binds to folate receptors in cancer cells. DSPE-PEG2000-Folate can be post-inserted into preformed liposomal bilayers to prepare folate-targeted liposomal formulations. DSPE-PEG2000-Folate forms micelles/lipid bilayers and can be used in studies of targeted drug delivery systems[2]. -
loading...loading...
-
-
Folate-FITC
0 ImagesCat. No.: HY-13615CAS No.: 583037-91-6Synonyms: EC-17Folate-FITC (EC-17) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The Folate-FITC maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively. -
loading...loading...
-
-
Ricorfotide vedotin
0 ImagesSynonyms: CBP-1008; LDC 10BRicorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma). -
loading...loading...
-
-
NVP-EVS459
0 ImagesNVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research. -
loading...loading...
-
-
Onvontatug
0 ImagesCat. No.: HY-P992124CAS No.: 3037073-85-8Synonyms: BAT8006 Antibody; BAT-6028Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer. -
loading...loading...
-
-
Eliroptamig
0 ImagesCat. No.: HY-P992112CAS No.: 3064817-30-4Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing. -
loading...loading...
-
-
Opugotamig olatansine
0 ImagesCat. No.: HY-185427Synonyms: IMGN-151Opugotamig olatansine (IMGN151) is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC). Opugotamig olatansine comprises antibody Opugotamig (HY-P990935) and linker-payload NMS-P945 (HY-185569). Opugotamig olatansine binds to two independent epitopes of FRα and promotes antibody binding, internalization, and processing. Opugotamig olatansine can be used for the research of FRα-positive ovarian cancer. -
loading...loading...
-
-
DBCO-PEG1000-FA
0 ImagesCat. No.: HY-W1123936BSynonyms: DBCO-PEG1000-FolateDBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications. -
loading...loading...
-
-
Lazatatug
0 ImagesCat. No.: HY-P991695CAS No.: 3035565-36-4Lazatatug is an anti-FOLR1 IgEκ type humanized antibody with antineoplastic activity. -
loading...loading...
-
-
CBP-1018
0 ImagesCBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer. -
loading...loading...
-
-
ZW-191
0 ImagesCat. No.: HY-185743ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer. -
loading...loading...
-
-
Sofetabart
0 ImagesCat. No.: HY-P992510Synonyms: LY-4170156 Antibody; MBK-103 Antibody -
loading...loading...
-
-
DBCO-PEG3400-FA
0 ImagesCat. No.: HY-W1123936DSynonyms: DBCO-PEG3400-FolateDBCO-PEG-FA (DBCO-PEG-Folate) (MW 3400) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications. -
loading...loading...
-
-
DBCO-PEG10000-FA
0 ImagesCat. No.: HY-W1123936HSynonyms: DBCO-PEG10000-FolateDBCO-PEG10000-FA (DBCO-PEG10000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications. -
loading...loading...
-
-
ZW-191 Antibody
0 ImagesCat. No.: HY-P992515ZW-191 Antibody is a humanized IgG1 antibody targeting folate receptor α (FRα). ZW-191 Antibody is conjugated with MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) to generate the antibody-drug conjugate (ADC) ZW-191 (HY-185743). ZW-191 Antibody-based ADC exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 Antibody is applicable to research related to ovarian cancer, non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer. -
loading...loading...
-
-
EC1454
0 ImagesCat. No.: HY-128937CAS No.: 1602487-15-9EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy. -
loading...loading...
-
-
EC-0225
0 ImagesCat. No.: HY-16181CAS No.: 926626-77-9EC-0225, a folate conjugate of two agents- one a potent microtubule inhibiting agent, and the second a DNA alkylating agent. EC-0225 inhibits the growth of folate receptor (FR)-positive KB cells with an IC50 of ~1 nM. EC-0225 can be selectively delivered to advanced FR-positive tumors without causing overt toxicity, such as lung carcinoma. -
loading...loading...
-
-
4A-BFA-11
0 ImagesCat. No.: HY-1805574A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (KD = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research. -
loading...loading...
-
-
Farletuzumab-LNK4-S (DAR4)
0 ImagesCat. No.: HY-185773AFarletuzumab-LNK4-S (DAR4) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 4. Farletuzumab-LNK4-S (DAR4) is prepared by conjugating the anti-FRα antibody Farletuzumab (HY-P99153) with LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR4) can be used in cancer-related research. -
loading...loading...
-
- 1
- 2
